BioCentury
ARTICLE | Finance

Ante Antengene

Why Qiming invested in Chinese in-licensing play Antengene

August 18, 2017 5:17 PM UTC

With a track record of bringing drugs to market in China, the founder of Chinese in-licensing play Antengene Corp. convinced Qiming Venture Partners to lead its $21 million series A round.

Antengene closed the round on Aug. 16. TF Capital, HG Capital and Tigermed Investment, the venture arm of Chinese CRO Hangzhou Tigermed Consulting Co. Ltd. (SZSE:300347), also participated...